SELLAS Life Sciences (SLS) Long-Term Debt Repayments (2010 - 2018)
SELLAS Life Sciences (SLS) reported Long-Term Debt Repayments of $76000.0 for Q4 2018, down 36.67% year-over-year from $120000.0 in Q4 2017, and down 98.9% on a QoQ basis from $6.9 million in Q3 2018.
SELLAS Life Sciences (SLS) has 9 years of Long-Term Debt Repayments data on file, last reported at $76000.0 in Q4 2018.
- Quarterly Long-Term Debt Repayments fell 36.67% year-over-year to $76000.0 in Q4 2018, while the trailing twelve-month figure through Sep 2019 was $76000.0 (down 99.01% YoY) and the FY2018 annual result came in at $7.6 million, up 1506.98% from the prior year.
- Long-Term Debt Repayments slipped to $76000.0 in Q4 2018 per SLS's latest filing, from $6.9 million in the prior quarter.
- Across five years, Long-Term Debt Repayments topped out at $6.9 million in Q3 2018 and bottomed at $1000.0 in Q3 2017.
- The 5-year median for Long-Term Debt Repayments is $858000.0 (2014), against an average of $1.1 million.
- The widest annual swing landed in 2017, when Long-Term Debt Repayments sank 90.61%; it then jumped 693500.0% in 2018.
- Tracing SLS's Long-Term Debt Repayments over 5 years: stood at $858000.0 in 2014, then advanced by 17.6% to $1.0 million in 2015, then decreased by 20.71% to $800000.0 in 2016, then sank by 85.0% to $120000.0 in 2017, then slumped by 36.67% to $76000.0 in 2018.
- Per Business Quant, the three latest SLS Long-Term Debt Repayments figures stand at $76000.0 (Q4 2018), $6.9 million (Q3 2018), and $589000.0 (Q1 2018).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 76,000.00 |
| Dec 31, 2018 | 76,000.00 |
| Sep 30, 2018 | 6.94 Mn |
| Sep 30, 2018 | 6.94 Mn |
| Mar 31, 2018 | 589,000.00 |
| Mar 31, 2018 | 589,000.00 |
| Dec 31, 2017 | 120,000.00 |
| Dec 31, 2017 | 120,000.00 |
| Sep 30, 2017 | 1,000.00 |
| Sep 30, 2017 | 1,000.00 |
| Jun 30, 2017 | 352,000.00 |
| Jun 30, 2017 | 352,000.00 |
| Dec 31, 2016 | 800,000.00 |
| Dec 31, 2016 | 800,000.00 |
| Jun 30, 2016 | 3.75 Mn |
| Jun 30, 2016 | 3.75 Mn |
| Mar 31, 2016 | 1.03 Mn |
| Mar 31, 2016 | 1.03 Mn |
| Dec 31, 2015 | 1.01 Mn |
| Dec 31, 2015 | 1.01 Mn |
| Sep 30, 2015 | 988,000.00 |
| Sep 30, 2015 | 988,000.00 |
| Jun 30, 2015 | 967,000.00 |
| Jun 30, 2015 | 967,000.00 |
| Mar 31, 2015 | 947,000.00 |
| Mar 31, 2015 | 947,000.00 |
| Dec 31, 2014 | 858,000.00 |
| Dec 31, 2014 | 858,000.00 |
| Sep 30, 2014 | 901,000.00 |
| Sep 30, 2014 | 901,000.00 |
| Jun 30, 2014 | 4,000.00 |
| Jun 30, 2014 | 4,000.00 |
| Mar 31, 2014 | 3,000.00 |
| Mar 31, 2014 | 3,000.00 |
| Dec 31, 2013 | 25,000.00 |
| Dec 31, 2013 | 25,000.00 |
| Sep 30, 2013 | -17,000.00 |
| Sep 30, 2013 | -17,000.00 |
| Jun 30, 2013 | 17,000.00 |
| Jun 30, 2013 | 17,000.00 |
| Jun 30, 2012 | 3,000.00 |
| Jun 30, 2012 | 3,000.00 |
| Mar 31, 2012 | 7,000.00 |
| Mar 31, 2012 | 7,000.00 |
| Dec 31, 2011 | 11,000.00 |
| Dec 31, 2011 | 11,000.00 |
| Sep 30, 2011 | 26,000.00 |
| Sep 30, 2011 | 26,000.00 |
| Jun 30, 2011 | 24,000.00 |
| Jun 30, 2011 | 24,000.00 |
| Mar 31, 2011 | 23,000.00 |
| Mar 31, 2011 | 23,000.00 |
| Dec 31, 2010 | 24,000.00 |
| Dec 31, 2010 | 24,000.00 |
| Sep 30, 2010 | 15,000.00 |
| Sep 30, 2010 | 15,000.00 |